Bristol MyersがNvidia SuperPODを購入 — 果たして創薬を加速できるのか?
bristol myers squibbが創薬目的でnvidia dgx superpodを購入。この動きは、製薬R&Dパイプラインへの垂直AI統合をめぐる競争の激化を示している。
bristol myers squibb is deploying an nvidia dgx superpod powered by the vera rubin architecture. the system aims to streamline artificial intelligence across its drug discovery and development workflows. it marks the first deployment of this architecture in the life sciences sector. this signals a shift from experimental ai tools to essential infrastructure for competitive biotech research.